Dose finding study on safety and efficacy of Anti-VEDF drugs for treatment for treatment of retinopathy of prematurity

Dose finding study on safety and efficacy of Anti-VEDF drugs for treatment for treatment of retinopathy of prematurity - Dose finding study on Anti-VEDF drugs for retinopathy of prematurity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016657

Enrollment

Registered

2015-02-27

Start date

2015-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinopathy of prematurity

Interventions

Intravitreal injection of anti-VEDF drugs

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: retinopathy of prematurity with progressive neovascular proliferation despite photocoagulation therapy

Exclusion criteria

Exclusion criteria: progressive retinal detachment wide area of neovascular proliferation aggressive posterior retinopathy of prematurity systemic abnormalities

Design outcomes

Primary

Measure	Time frame
Stabilization of retinopathy of prematurity and safety	—

Countries

Japan

Contacts

Public ContactNoriyuki Azuma

National Center for Child Health and Development Department of Ophthalmology & Laboratory for Visual Science

azuma-n@ncchd.go.jp03-3416-0181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026